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ABSTRACT
Transcriptional factors (TFs) and many of their target
genes are involved in gene regulation at the level of
transcription. To decipher gene regulatory networks
(GRNs) we require a comprehensive and accurate
knowledge of transcriptional regulatory elements.
TRED (http://rulai.cshl.edu/TRED) was designed as a
resource for gene regulation and function studies. It
collects mammalian cis- and trans-regulatory ele-
ments together with experimental evidence. All the
regulatory elements were mapped on to the assem-
bled genomes. In this new release, we included a
total of 36 TF families involved in cancer. Accor-
dingly, the number of target promoters and genes for
TF families has increased dramatically. There are
11660 target genes (7479 in human, 2691 in mouse
and 1490 in rat) and 14908 target promoters (10225
in human, 2985 in mouse and 1698 in rat). Addi-
tionally, we constructed GRNs for each TF family by
connecting the TF–target gene pairs. Such interac-
tion data between TFs and their target genes will
assist detailed functional studies and help to obtain a
panoramic view of the GRNs for cancer research.
OVERVIEW
TRED was originally designed as a resource for studies on
gene function and regulation. It provides cis-elements, such
as promoters and binding motifs, and trans-elements, such
as transcriptional factors (TFs). The promoters of target
genes came from two sources: experimental determination
and sequence-based computational prediction. These two
sources complement each other. In TRED, hand curation
was applied as a crucial part of the data collection to ensure
data accuracy. Based on the reliability of the supporting
evidence for each promoter, a quality level was assigned.
One key feature of TRED is the easy access to interaction
data between TFs and the promoters of their target genes,
including binding motifs reported by the previous studies.
Although part of the data was obtained from the existing
gene regulation resources, most of the data came from our
exhaustive literature curation. The TF-binding motifs were
mapped on to the promoter sequences of their target genes.
Along with the binding motifs, the experimental evidence
and other important pertinent information were also collec-
ted. A binding quality level was assigned based on deﬁnitive-
ness of the binding evidence, which was determined by the
experimental approaches employed to demonstrate the bind-
ing and data interpretation from experts. For example, we
assigned ‘known’ as the binding quality level to a binding
that has been proved by gel-shift competition, DNase I
footprinting, etc.
In order to provide users with more complete information
of the genes, cross-references to other well-known database
such as PubMed, GenBank, GeneCards (1) and TRANSFAC
(2) were established in TRED. A comprehensive description
of the content and the structure of TRED has been published
earlier (3). In addition, many on-the-ﬂy tools were imple-
mented for the analysis of sequences retrieved from TRED
as well as imported from other resources. The user interface
and software functionality were also described in the previous
report (3).
RECENT DEVELOPMENTS
New entries
Upon the emergence of high-throughput technologies, a
huge amount of large-scale gene expression and regulation
proﬁling data have been made available by microarray
and chromatin immunoprecipitation (chip-ChIP) studies. To
uncover GRNs among the identiﬁed genes would require
the knowledge of their promoter sequences. We used our
promoter prediction program FirstEF (4) to predict promoters
in the genomes of human, mouse and rat. These promoters
were then combined with the known promoters extracted
from EPD (5), DBTSS (6), GenBank, etc and were deposited
in our database CSHLmpd (7). It should be noted
that CSHLmpd also contains genes without any promoter.
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genome assembly is lower than that of the previous version
after removal of the redundancy. However, the number of
known promoters and their related genes are close in both
versions. There are more promoters than genes in each spe-
cies due to alternative transcription start sites in many
genes (7). Table 1 gives the statistics of promoters and
genes in each quality category.
The human genome codes for  1850 TFs, which account
for 6.0% of its estimated total number of genes (8). It is a
daunting task to collect and curate comprehensive and precise
interaction data between the TFs and their target genes. Since
cancer is one of the greatest threats to human health and has
been a ﬁeld under extensive study, including a broad interest
in understanding cell cycle regulatory networks, we started
out by focusing on target genes of cancer-related TFs. Previ-
ously, TRED contained mainly the target genes and promot-
ers for TF families E2F and Myc (3). In this new release, we
expanded it to 34 new TF families that have been implicated
in cancer pathways, including p53, AP1, ER and NFkB/Rel.
They are involved in many cellular processes, such as prolif-
eration, differentiation, cell motility and apoptosis. There are
totally 9308 newly collected target genes (5365 in human,
2526 in mouse and 1417 in rat) and 10251 target promoters
(5956 in human, 2736 in mouse and 1559 in rat) for these TF
families. The detailed distribution of the target promoters and
the target genes is listed in Table 2.
Although TRANSFAC also provides factor-site interaction
data, it contains less information for the TFs and their target
genes available in TRED. Its latest version (version 7.0)
has collected 1040 factors and 608 genes for human and
765 factors and 417 genes for mouse (2). Therefore, on
average each factor has less than one target gene. In contrast,
the number of target genes per TF in TRED is much high-
er. For example, there are >200 target genes on average for
each TF family for human in TRED (Table 2). This can
provide fairly resolved gene regulatory networks (GRNs)
for the 36 TF families involved in cancer pathways. In addi-
tion to this, TRED contains relatively complete genome-wide
promoter annotation for human, mouse and rat. Moreover, the
binding sites in TRED were also mapped on to the assembled
chromosomes. These absolute genomic positions make it
ready to associate TRED with other genomic data for various
studies. However, it should be noted that TRANSFAC also
collects factor–site interaction data of species other than
human, mouse and rat. Therefore, although TRED and
TRANSFAC overlap to certain extent, they complement
each other at some aspects.
Other development
The accurate and comprehensive knowledge of transcrip-
tional regulatory elements in TRED allows one to construct
the GRNs for a given TF family by bringing all TF–target
gene pairs together. In our initial analysis, we found that
some TFs are the target genes of other TFs and often more
than one TFs control the expression of the same gene. Fur-
thermore, some target genes affect the expression or stability
of TFs by feedback loop. As an example, Figure 1 shows a
simpliﬁed GRN for TF family GLI (glioma-associated onco-
gene homolog). For the TF families with hundreds of target
genes, such as AP1, CEBP and ETS, they would form more
complex networks. There are cross talks between the
Table 1. Number of promoters and genes in TRED, with gene numbers in parentheses
Promoter quality 1 2 3 4 5 + 6 Sum
Human 1842 (1767) 13619 (10115) 5311 (5150) 7305 (6738) 26684 (15222) 54761 (27016)
Mouse 172 (156) 8407 (6552) 6551 (6449) 4250 (4041) 23500 (15185) 42880 (25751)
Rat 91 (82) 996 (680) 3374 (3333) 2917 (2834) 25681 (16346) 33059 (21440)
Promoter qualities are ranked from high to low: 1, known,curated promoters; 2, known, pipeline collected promoters; 3, predicted promoters with Refseq evidence
andputativepromoterstaking50 endsofRefseqasTSS;4,predictedpromoterswithmRNA(otherthanRefseqandEST)evidence;5,predictedpromoterswithEST
evidence; 6, predicted promoters supported only by gene prediction. Promoters included in a higher ranking are automatically excluded from the lower ranking
categories.
Table 2. Number of curated target promoters/genes for the 36 TF families
TF Human Mouse Rat
AP1 432/383 217/190 157/143
AP2 338/318 123/123 90/86
AR 69/49 19/19 24/15
ATF 189/173 59/59 26/26
BCL 21/19 15/15 0/0
BRCA 20/20 4/4 0/0
CEBP 335/325 152/134 241/179
CREB 224/220 138/133 95/93
E2F 1593/1329 141/127 11/11
EGR 120/111 67/55 33/26
ELK 47/41 15/13 6/6
ER 169/152 40/39 32/31
ERG 21/21 5/5 0/0
ETS 445/412 207/196 51/51
FLI1 41/41 17/16 0/0
GLI 16/16 8/8 0/0
HIF 119/112 63/60 29/29
HLF 10/10 5/5 2/2
HOX 65/57 93/81 5/5
LEF 40/33 26/23 5/5
MYB 253/239 40/40 6/6
MYC 2676/785 108/38 128/62
NFI 136/127 75/62 73/65
OCT 232/195 123/108 34/34
p53 337/313 135/130 32/30
PAX 52/47 76/61 13/11
PPAR 149/149 125/124 88/84
PR 31/27 14/14 10/10
RAR 233/218 71/71 40/40
REL 445/396 202/181 87/87
SMAD 139/130 76/75 17/17
SP 655/515 296/263 235/220
STAT 245/218 111/106 48/46
TAL1 15/14 9/6 0/0
USF 235/215 94/91 72/62
WT1 78/49 16/16 8/8
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genes or through direct interactions between the members
of different TF families. The experimental evidence for
each interaction between a TF and its target gene is available
through the references provided in TRED. This is an advan-
tage over other networks computationally predicted from
expression and/or phylogenetic proﬁles. In this release,
GRNs for the TF families have been generated from the col-
lected interaction data and statically stored in TRED. The
dynamic links to GRNs will be provided in the query result
in the future. Taken together, TRED can facilitate to decipher
the GRNs and help researchers to better understand the gene
regulatory mechanisms.
DATA ACCESS
The website (http://rulai.cshl.edu/TRED) offers the following
services: easy access to TRED entries through text-based
query interface; search for the target genes of a given TF;
retrieval of the promoter sequences and the TF-binding
motifs; further analysis of the retrieved sequences of promot-
ers and motifs. TRED homepage also provides the access to
the GRNs of the TF families in human, mouse and rat, which
were constructed from its collection of the interaction data
between the TFs and their target genes.
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